Diane Merino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diane Merino has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Milou-Daniel Drici
Department of Clinical Pharmacology, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France
16 shared publications - Alexandre Olivier Gérard
Department of Clinical Pharmacology Université Côte d'Azur, University Hospital Centre of Nice Nice France
15 shared publications - Susanne Thümmler
Université Côte d'Azur, CoBTek Nice France
8 shared publications - Alexandre Destere
Department of Clinical Pharmacology, University Hospital Centre Nice Pasteur Hospital, 06000 Nice, France; Université Côte d’Azur, Inria, CNRS, Laboratoire J.A. Dieudonné, Maasai team, 06000 Nice, France
5 shared publications Fanny Rocher
Department of Clinical Pharmacology, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France
5 shared publicationsAlexandre Destere
Department of Clinical Pharmacology, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France
4 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Mental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase
Rationale: CFTR modulators (CFTRms) have transformed cystic fibrosis care, yet concern exists regarding their mental health safety profile. Objective: To provide further information, we conducted an analysis of CFTRm-related mental health disorders using two spontaneous pharmacovigilance reporting databases in real-world settings. Methods: We analyzed reports from the French Pharmacovigilance Database (FPD) and VigiBase, the WHO global individual case safety reports database. Reports recorded between 2012 and 2024 involving any CFTRm and psychiatric disorders were included. In VigiBase, we conducted a case-non case, disproportionality analysis using the Reporting Odds Ratio (ROR), overall and stratified by age group (pediatrics vs. adults) and by CFTRm type. This study was conducted in accordance with the STROBE and the READUS-PV guidelines. Results: In the FPD, 116 cases were analyzed. ELX/TEZ/IVA was suspected in 98% of cases and no single case was reported with ivacaftor alone. Sleep (61%), mood (37%), and anxiety disorders (27%) were the most frequently reported, with suicidal behaviors being infrequent, including 6 suicide attempts and no completed suicide. In VigiBase (n = 3,407), sleep disorders predominated in children, whereas mood and suicidality disorders were most frequent in adolescents. The median time to onset was 60 days (Q1-Q3: 12—150 days). Mental health disorders were disproportionately reported with CFTRms, particularly ELX/TEZ/IVA, while they were not with other combination therapies, compared to other drugs in the database. Disproportionality signals were slightly stronger in pediatrics than in adults. Conclusions: CFTRms, especially ELX/TEZ/IVA, are associated with increased reporting of mental health disorders, predominantly sleep and mood disorders. Pediatrics appear to be particularly affected. Prospective observational studies are warranted to confirm these findings and elucidate underlying pathophysiological mechanisms. Registration: OSF: mfyx3
- 7 September 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Open AccessMental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase
Rationale: CFTR modulators (CFTRms) have transformed cystic fibrosis care, yet concern exists regarding their mental health safety profile. Objective: To provide further information, we conducted an analysis of CFTRm-related mental health disorders using two spontaneous pharmacovigilance reporting databases in real-world settings. Methods: We analyzed reports from the French Pharmacovigilance Database (FPD) and VigiBase, the WHO global individual case safety reports database. Reports recorded between 2012 and 2024 involving any CFTRm and psychiatric disorders were included. In VigiBase, we conducted a case-non case, disproportionality analysis using the Reporting Odds Ratio (ROR), overall and stratified by age group (pediatrics vs. adults) and by CFTRm type. This study was conducted in accordance with the STROBE and the READUS-PV guidelines. Results: In the FPD, 116 cases were analyzed. ELX/TEZ/IVA was suspected in 98% of cases and no single case was reported with ivacaftor alone. Sleep (61%), mood (37%), and anxiety disorders (27%) were the most frequently reported, with suicidal behaviors being infrequent, including 6 suicide attempts and no completed suicide. In VigiBase (n = 3,407), sleep disorders predominated in children, whereas mood and suicidality disorders were most frequent in adolescents. The median time to onset was 60 days (Q1-Q3: 12—150 days). Mental health disorders were disproportionately reported with CFTRms, particularly ELX/TEZ/IVA, while they were not with other combination therapies, compared to other drugs in the database. Disproportionality signals were slightly stronger in pediatrics than in adults. Conclusions: CFTRms, especially ELX/TEZ/IVA, are associated with increased reporting of mental health disorders, predominantly sleep and mood disorders. Pediatrics appear to be particularly affected. Prospective observational studies are warranted to confirm these findings and elucidate underlying pathophysiological mechanisms. Registration: OSF: mfyx3
- Open Access
- 21 December 2025
- Published by Elsevier in Psychiatry Research
- Vol. 356, 116920
Alice in wonderland syndrome: Down the rabbit hole of VigiBase®
- 21 December 2025
- Published by Elsevier in Psychiatry Research
- Vol. 356, 116920
Open AccessAlice in wonderland syndrome: Down the rabbit hole of VigiBase®
- Open Access
- 11 August 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-9
Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database
Belatacept is a co-stimulation blocker used in kidney transplant recipients to prevent allograft rejection. Unlike calcineurin inhibitors, belatacept is non-nephrotoxic and may carry a lower risk of cardiovascular and metabolic complications. However, the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) includes a broad range of adverse drug reactions (ADRs), mostly identified in small clinical trials with cyclosporine as a control, in patients exposed to other immunosuppressants. As real-world data on belatacept safety accumulate, a reassessment of its safety profile becomes essential. We analyzed pharmacovigilance data from VigiBase®, the World Health Organization global safety database, to explore discrepancies between postmarketing ADR reports and the belatacept Summary of Product Characteristics (SmPC). A disproportionality analysis was performed using the Information Component, a Bayesian metric, to identify potential pharmacovigilance signals. We retrieved 2795 reports involving belatacept, including 424 (15.2%) fatal cases. The disproportionality analysis highlighted 51 potential signals that were not explicitly listed in the SmPC, such as Clostridium difficile infection, hepatitis B reactivation, and hemophagocytic lymphohistiocytosis. Conversely, 47 (33.1%) of the 142 ADRs classified as “common” or “very common” in the SmPC, such as Cushing’s syndrome or depression, had fewer than three reports in VigiBase®. This study highlights discrepancies between the belatacept SmPC and real-world pharmacovigilance data. Several labeled ADRs were not reported frequently in VigiBase®, suggesting that they may be less commonly observed in real-world settings. Others, particularly infections, warrant further scrutiny. Yet, these findings should be interpreted with caution due to the inherent limitations of pharmacovigilance data, including underreporting, reporting bias, and residual confounding. Pharmacovigilance approaches generate signals, but cannot definitively establish or exclude a causal relationship. Nonetheless, these findings suggest the need for periodic reassessment of belatacept’s safety profile to ensure accurate and clinically relevant information for healthcare providers.
- 11 August 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-9
Open AccessSafety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database
Belatacept is a co-stimulation blocker used in kidney transplant recipients to prevent allograft rejection. Unlike calcineurin inhibitors, belatacept is non-nephrotoxic and may carry a lower risk of cardiovascular and metabolic complications. However, the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) includes a broad range of adverse drug reactions (ADRs), mostly identified in small clinical trials with cyclosporine as a control, in patients exposed to other immunosuppressants. As real-world data on belatacept safety accumulate, a reassessment of its safety profile becomes essential. We analyzed pharmacovigilance data from VigiBase®, the World Health Organization global safety database, to explore discrepancies between postmarketing ADR reports and the belatacept Summary of Product Characteristics (SmPC). A disproportionality analysis was performed using the Information Component, a Bayesian metric, to identify potential pharmacovigilance signals. We retrieved 2795 reports involving belatacept, including 424 (15.2%) fatal cases. The disproportionality analysis highlighted 51 potential signals that were not explicitly listed in the SmPC, such as Clostridium difficile infection, hepatitis B reactivation, and hemophagocytic lymphohistiocytosis. Conversely, 47 (33.1%) of the 142 ADRs classified as “common” or “very common” in the SmPC, such as Cushing’s syndrome or depression, had fewer than three reports in VigiBase®. This study highlights discrepancies between the belatacept SmPC and real-world pharmacovigilance data. Several labeled ADRs were not reported frequently in VigiBase®, suggesting that they may be less commonly observed in real-world settings. Others, particularly infections, warrant further scrutiny. Yet, these findings should be interpreted with caution due to the inherent limitations of pharmacovigilance data, including underreporting, reporting bias, and residual confounding. Pharmacovigilance approaches generate signals, but cannot definitively establish or exclude a causal relationship. Nonetheless, these findings suggest the need for periodic reassessment of belatacept’s safety profile to ensure accurate and clinically relevant information for healthcare providers.
- Open Access
- 10 June 2025
- Published by Wiley in British Journal of Clinical Pharmacology
Evaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers
Aims: In medical education, the ability of large language models (LLMs) to match human performance raises questions about their potential as educational tools. This study evaluates LLMs' performance on Clinical Pharmacology and Therapeutics (CPT) exams, comparing their results to medical students and exploring their ability to identify poorly formulated multiple‐choice questions (MCQs).Methods: ChatGPT‐4 Omni, Gemini Advanced, Le Chat and DeepSeek R1 were tested on local CPT exams (third year of bachelor's degree, first/second year of master's degree) and the European Prescribing Exam (EuroPE+). The exams included MCQs and open‐ended questions assessing knowledge and prescribing skills. LLM results were analysed using the same scoring system as students. A confusion matrix was used to evaluate the ability of ChatGPT and Gemini to identify ambiguous/erroneous MCQs.Results: LLMs achieved comparable or superior results to medical students across all levels. For local exams, LLMs outperformed M1 students and matched L3 and M2 students. In EuroPE+, LLMs significantly outperformed students in both the knowledge and prescribing skills sections. All LLM errors in EuroPE+ were genuine (100%), whereas local exam errors were frequently due to ambiguities or correction flaws (24.3%). When both ChatGPT and Gemini provided the same incorrect answer to an MCQ, the specificity for detecting ambiguous questions was 92.9%, with a negative predictive value of 85.5%.Conclusion: LLMs demonstrate capabilities comparable to or exceeding medical students in CPT exams. Their ability to flag potentially flawed MCQs highlights their value not only as educational tools but also as quality control instruments in exam preparation.
- 10 June 2025
- Published by Wiley in British Journal of Clinical Pharmacology
Open AccessEvaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers
Aims: In medical education, the ability of large language models (LLMs) to match human performance raises questions about their potential as educational tools. This study evaluates LLMs' performance on Clinical Pharmacology and Therapeutics (CPT) exams, comparing their results to medical students and exploring their ability to identify poorly formulated multiple‐choice questions (MCQs).Methods: ChatGPT‐4 Omni, Gemini Advanced, Le Chat and DeepSeek R1 were tested on local CPT exams (third year of bachelor's degree, first/second year of master's degree) and the European Prescribing Exam (EuroPE+). The exams included MCQs and open‐ended questions assessing knowledge and prescribing skills. LLM results were analysed using the same scoring system as students. A confusion matrix was used to evaluate the ability of ChatGPT and Gemini to identify ambiguous/erroneous MCQs.Results: LLMs achieved comparable or superior results to medical students across all levels. For local exams, LLMs outperformed M1 students and matched L3 and M2 students. In EuroPE+, LLMs significantly outperformed students in both the knowledge and prescribing skills sections. All LLM errors in EuroPE+ were genuine (100%), whereas local exam errors were frequently due to ambiguities or correction flaws (24.3%). When both ChatGPT and Gemini provided the same incorrect answer to an MCQ, the specificity for detecting ambiguous questions was 92.9%, with a negative predictive value of 85.5%.Conclusion: LLMs demonstrate capabilities comparable to or exceeding medical students in CPT exams. Their ability to flag potentially flawed MCQs highlights their value not only as educational tools but also as quality control instruments in exam preparation.
- Open Access
- 15 March 2025
- Published by Elsevier in Neuropsychiatrie de l'Enfance et de l'Adolescence
- Vol. 73 (3) , 133-137
Apports des données en vie réelle à la sécurité des antipsychotiques chez l’enfant et l’adolescent
- 15 March 2025
- Published by Elsevier in Neuropsychiatrie de l'Enfance et de l'Adolescence
- Vol. 73 (3) , 133-137
Open AccessApports des données en vie réelle à la sécurité des antipsychotiques chez l’enfant et l’adolescent
- Open Access
- 14 February 2024
- Published by Elsevier in Psychiatry Research
- Vol. 334, 115786
Cardiac and metabolic safety profile of antipsychotics in youths: A WHO safety database analysis
- 14 February 2024
- Published by Elsevier in Psychiatry Research
- Vol. 334, 115786
Open AccessCardiac and metabolic safety profile of antipsychotics in youths: A WHO safety database analysis
- Open Access
- 16 August 2023
- Published by Elsevier in Psychiatry Research
- Vol. 327, 115415
Iatrogenic triggers for anorexia nervosa and bulimia nervosa: A WHO safety database disproportionality analysis
- 16 August 2023
- Published by Elsevier in Psychiatry Research
- Vol. 327, 115415
Open AccessIatrogenic triggers for anorexia nervosa and bulimia nervosa: A WHO safety database disproportionality analysis
- Open Access
- 12 June 2023
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 33 (5) , 1383-1393
Drug-related catatonia in youths: real-world insights from the WHO Safety Database
Catatonia is characterized by psychomotor alterations and reduced contact with the environment. Initially linked to schizophrenia, it also occurs in mood disorders or organic conditions. In children, catatonia remains poorly delineated, despite dramatically increasing the risk of premature death. As data on pediatric drug-induced catatonia bears many uncertainties, we aimed to characterize its age-dependent patterns, using real-world data from the WHO safety database (VigiBase®).VigiBase® was queried for all reports of catatonia registered up to December 8th 2022. Reports involving patients <18 years were classified into 3 groups: ≤23 months, 2–11 years, and 12–17 years. Disproportionality analyses relied on the Reporting Odds Ratio (ROR), and the positivity of the lower end of the 95% confidence interval of the Information Component (IC) was required to suspect a signal. Catatonia was evoked in 421 pediatric reports. In infants, vaccines were leading. In children, the main signals involved haloperidol (ROR 104.3; 95% CI 45.6–238.5), ondansetron (ROR 40.5; 95% CI 16.5–99.5), and ciclosporin (ROR 27.4; 95% CI 13.8–54.1). In adolescents, chlorpromazine (ROR 199.1; 95% CI 134.8–294.1), benzatropine (ROR 193; 95% CI 104.1–361.6), and olanzapine (ROR 135.7; 95% CI 104.6–175.9) reached the highest RORs. In infants, catatonia was related to vaccines, it was ascribed to multiple drugs in children, and mainly to psychotropic drugs in adolescents. Less suspected drugs, such as ondansetron, were highlighted. Despite limitations inherent in spontaneous reporting systems, this study supports that a careful anamnesis is warranted to separate catatonia associated with medical conditions from drug-induced catatonia in pediatric patients.
- 12 June 2023
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 33 (5) , 1383-1393
Open AccessDrug-related catatonia in youths: real-world insights from the WHO Safety Database
Catatonia is characterized by psychomotor alterations and reduced contact with the environment. Initially linked to schizophrenia, it also occurs in mood disorders or organic conditions. In children, catatonia remains poorly delineated, despite dramatically increasing the risk of premature death. As data on pediatric drug-induced catatonia bears many uncertainties, we aimed to characterize its age-dependent patterns, using real-world data from the WHO safety database (VigiBase®).VigiBase® was queried for all reports of catatonia registered up to December 8th 2022. Reports involving patients <18 years were classified into 3 groups: ≤23 months, 2–11 years, and 12–17 years. Disproportionality analyses relied on the Reporting Odds Ratio (ROR), and the positivity of the lower end of the 95% confidence interval of the Information Component (IC) was required to suspect a signal. Catatonia was evoked in 421 pediatric reports. In infants, vaccines were leading. In children, the main signals involved haloperidol (ROR 104.3; 95% CI 45.6–238.5), ondansetron (ROR 40.5; 95% CI 16.5–99.5), and ciclosporin (ROR 27.4; 95% CI 13.8–54.1). In adolescents, chlorpromazine (ROR 199.1; 95% CI 134.8–294.1), benzatropine (ROR 193; 95% CI 104.1–361.6), and olanzapine (ROR 135.7; 95% CI 104.6–175.9) reached the highest RORs. In infants, catatonia was related to vaccines, it was ascribed to multiple drugs in children, and mainly to psychotropic drugs in adolescents. Less suspected drugs, such as ondansetron, were highlighted. Despite limitations inherent in spontaneous reporting systems, this study supports that a careful anamnesis is warranted to separate catatonia associated with medical conditions from drug-induced catatonia in pediatric patients.
- Open Access
- 11 May 2023
- Published by Springer Nature in BioDrugs
- Vol. 37 (4) , 521-530
CAR-T Cells and the Kidney: Insights from the WHO Safety Database
Background Chimeric antigen receptor T (CAR-T) cells have proven to be a game changer for treating several hematologic malignancies. Randomized controlled trials have highlighted potential life-threatening adverse drug reactions (ADRs), including cytokine release syndrome (CRS). Acute renal failure (ARF) has also been reported in 20% of the patients treated. However, an analysis of renal safety supported by large-scale real-life data seems warranted. Patients and methods We queried VigiBase® for all reports of the Standardised MedDRA Query “acute renal failure” (ARF) involving a CAR-T cell, registered until 24 July 2022. Disproportionality for this ADR was analyzed through calculation of the Information Component [IC (95% confidence interval)]. A positive lower end of the 95% confidence interval of the IC is the threshold used in statistical signal detection in VigiBase®. The same analysis was carried out for various hydroelectrolytic disorders. Results We gathered 224 reports of ARF, and 125 reports of hydroelectrolytic disorders involving CAR-T cells. CAR-T cells were disproportionately reported with ARF [IC 1.5 (1.3–1.7)], even after excluding reports mentioning CRS. A significant disproportionate reporting was also found for hypernatremia [IC 3.1 (2.2–3.8)], hyperphosphatemia [IC 3.1 (1.8–3.9)], hypophosphatemia [IC 2.0 (0.6–2.9)], metabolic acidosis [IC 1.8 (1.2–2.2)], hyponatremia [IC 1.6 (1.1–2.0)], and hypercalcemia [IC 1.4 (0.5–2.1)]. There was no disproportionate reporting of dyskalemia. Conclusions This study is limited by the inherent flaws of pharmacovigilance approaches. Nonetheless, our findings suggest that ARF and an array of hydroelectrolytic disorders are potential ADRs of CAR-T cell therapy, in real-life settings and in a nonselected population.
- 11 May 2023
- Published by Springer Nature in BioDrugs
- Vol. 37 (4) , 521-530
Open AccessCAR-T Cells and the Kidney: Insights from the WHO Safety Database
Background Chimeric antigen receptor T (CAR-T) cells have proven to be a game changer for treating several hematologic malignancies. Randomized controlled trials have highlighted potential life-threatening adverse drug reactions (ADRs), including cytokine release syndrome (CRS). Acute renal failure (ARF) has also been reported in 20% of the patients treated. However, an analysis of renal safety supported by large-scale real-life data seems warranted. Patients and methods We queried VigiBase® for all reports of the Standardised MedDRA Query “acute renal failure” (ARF) involving a CAR-T cell, registered until 24 July 2022. Disproportionality for this ADR was analyzed through calculation of the Information Component [IC (95% confidence interval)]. A positive lower end of the 95% confidence interval of the IC is the threshold used in statistical signal detection in VigiBase®. The same analysis was carried out for various hydroelectrolytic disorders. Results We gathered 224 reports of ARF, and 125 reports of hydroelectrolytic disorders involving CAR-T cells. CAR-T cells were disproportionately reported with ARF [IC 1.5 (1.3–1.7)], even after excluding reports mentioning CRS. A significant disproportionate reporting was also found for hypernatremia [IC 3.1 (2.2–3.8)], hyperphosphatemia [IC 3.1 (1.8–3.9)], hypophosphatemia [IC 2.0 (0.6–2.9)], metabolic acidosis [IC 1.8 (1.2–2.2)], hyponatremia [IC 1.6 (1.1–2.0)], and hypercalcemia [IC 1.4 (0.5–2.1)]. There was no disproportionate reporting of dyskalemia. Conclusions This study is limited by the inherent flaws of pharmacovigilance approaches. Nonetheless, our findings suggest that ARF and an array of hydroelectrolytic disorders are potential ADRs of CAR-T cell therapy, in real-life settings and in a nonselected population.
- Open Access
- 18 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2972
Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis
Antipsychotic drugs (APs) aim to treat schizophrenia, bipolar mania, and behavioral symptoms. In child psychiatry, despite limited evidence regarding their efficacy and safety, APs are increasingly subject to off-label use. Studies investigating addictology-related symptoms in young people being scarce, we aimed to characterize the different patterns of AP misuse and withdrawal in children and adolescents relying on the WHO pharmacovigilance database (VigiBase®, Uppsala Monitoring Centre, Sweden). Using the standardized MedDRA Query ‘drug abuse, dependence and withdrawal’, disproportionality for each AP was assessed with the reporting odds ratio and the information component. A signal was detected when the lower end of the 95% confidence interval of the information component was positive. Results revealed mainly withdrawal symptoms in infants (under 2 years), intentional misuse in children (2 to 11 years), and abuse in adolescents (12 to 17 years). Olanzapine, risperidone, aripiprazole, and quetiapine were disproportionately reported in all age groups, with quetiapine being subject to a specific abuse signal in adolescents. Thus, in adolescents, the evocation of possible recreational consumption may lead to addiction-appropriate care. Further, in young patients with a history of AP treatment, a careful anamnesis may allow one to identify misuse and its role in the case of new-onset symptoms.
- 18 November 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2972
Open AccessAntipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis
Antipsychotic drugs (APs) aim to treat schizophrenia, bipolar mania, and behavioral symptoms. In child psychiatry, despite limited evidence regarding their efficacy and safety, APs are increasingly subject to off-label use. Studies investigating addictology-related symptoms in young people being scarce, we aimed to characterize the different patterns of AP misuse and withdrawal in children and adolescents relying on the WHO pharmacovigilance database (VigiBase®, Uppsala Monitoring Centre, Sweden). Using the standardized MedDRA Query ‘drug abuse, dependence and withdrawal’, disproportionality for each AP was assessed with the reporting odds ratio and the information component. A signal was detected when the lower end of the 95% confidence interval of the information component was positive. Results revealed mainly withdrawal symptoms in infants (under 2 years), intentional misuse in children (2 to 11 years), and abuse in adolescents (12 to 17 years). Olanzapine, risperidone, aripiprazole, and quetiapine were disproportionately reported in all age groups, with quetiapine being subject to a specific abuse signal in adolescents. Thus, in adolescents, the evocation of possible recreational consumption may lead to addiction-appropriate care. Further, in young patients with a history of AP treatment, a careful anamnesis may allow one to identify misuse and its role in the case of new-onset symptoms.